Compare iShares MSCI Singapore ETF (EWS) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Singapore ETF vs Cassava Sciences Inc — how do they compare? iShares MSCI Singapore ETF trades at $31.81, while Cassava Sciences Inc trades at $1.08 (market cap $53.14M). The key difference: iShares MSCI Singapore ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| EWS | FLNA | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $32.09 | $4.64 |
52-Week Low | $26.47 | $1.09 |
Market Cap | — | $53.14M |
Enterprise Value | — | -$33.43M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Singapore ETF
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
